← Browse by Condition
Medical Condition

inflammatory cardiomyopathy

Total Trials
3
Recruiting Now
3
Trial Phases
Phase 2, Phase 3

ClinicalMetric tracks all active clinical trials for inflammatory cardiomyopathy sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — inflammatory cardiomyopathy Clinical Trials

How many clinical trials are currently recruiting for inflammatory cardiomyopathy?
ClinicalMetric currently tracks 3 actively recruiting clinical trials for inflammatory cardiomyopathy, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 3. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for inflammatory cardiomyopathy?
inflammatory cardiomyopathy research spans Phase 2 (1 trial), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a inflammatory cardiomyopathy clinical trial?
Eligibility criteria for inflammatory cardiomyopathy trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 2
1
Phase 3
1
Top Sponsors
Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia 1 trial
Tongji Hospital 1 trial
Scientific Institute San Raffaele 1 trial

Recruiting Clinical Trials

NCT06898762
Recruiting

Creation of a National Multicenter Platform for the Study of Inflammatory Myocardial Disease: Pre-MYO Cohort

Enrollment
3,000 pts
Location
Spain
Sponsor
Fundacion para la Formacion e ...
View Trial →
NCT05961202 Phase 2, Phase 3
Recruiting

The Effects of Hydroxychloroquine in Patients with Inflammatory Cardiomyopathy

Enrollment
200 pts
Location
China
Sponsor
Tongji Hospital
View Trial →
NCT04521790
Recruiting

Role of Endomyocardial Biopsy and Aetiology-based Treatment in Patients With Inflammatory Heart Disease in Arrhythmic and Non-arrhythmic Clinical Presentations: an Integrated Approach for the Optimal Diagnostic and Therapeutic Management

Enrollment
1,000 pts
Location
Italy
Sponsor
Scientific Institute San Raffa...
View Trial →
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology